Regulated transgene expression may reduce transgene-specific and genotoxic risks associated with gene therapy. To prove this concept, we have investigated the suitability of doxycycline (Dox)-inducible human cytidine deaminase (hCDD) overexpression from lentiviral vectors to mediate effective myeloprotection while circumventing the lymphotoxicity observed with constitutive CDD activity. Rapid Dox-mediated transgene induction associated with a 6-17-fold increase in drug resistance was observed in 32D and primary murine bone marrow (BM) cells. Moreover, robust Dox-regulated transgene expression in the entire haematopoietic system was demonstrated for primary and secondary recipients of hCDD-transduced R26-M2rtTA transgenic BM cells. Furthermore, mice were significantly protected from myelosuppressive chemotherapy as evidenced by accelerated recovery of granulocytes (1.9 ± 0.6 vs 1.3 ± 0.3, P ¼ 0.034) and platelets (883 ± 194 vs 584 ± 160 10 3 per ml, P ¼ 0.011). Minimal transgene expression in the non-induced state and no overt cellular toxicities including lymphotoxicity were detected. Thus, using a relevant murine transplant model our data provide conclusive evidence that drug-resistance transgenes can be expressed in a regulated fashion in the lymphohaematopoietic system, and that Dox-inducible systems may be used to reduce myelotoxic side effect of anticancer chemotherapy or to avoid side effects of high constitutive transgene expression.
INTRODUCTION
While haematopoietic gene therapy has been shown to represent a promising and successful therapeutic option for a number of congenital diseases and in particular immunodeficiency disorders, [1] [2] [3] [4] these studies also have highlighted the problems still associated with this approach. Insertional mutagenesis leading to the clinical manifestation of leukaemias represents the most noticeable and serious side effect, 4, 5 but also specific transgeneinduced toxicities [6] [7] [8] or transgene-directed immune reactions can pose serious risks. To circumvent or at least reduce these problems, the use of regulated gene transfer systems, allowing for temporary-controlled transgene expression has been suggested and this strategy appears particularly feasible for gene therapy approaches in which expression of the therapeutic transgene only is required for defined time periods.
A number of regulated gene expression systems incorporating different promoter-regulatory elements have been explored. Although some of these systems exploit promoters responsive to specific chemical or physical stimuli, such as metal iones, 9 temperature 10 or O 2 saturation, 11 regulatable systems based on the application of drugs, such rapamycin 12 or the steroid hormones mifepristone or tamoxifen, 13, 14 currently offer powerful alternatives. In particular, tetracycline-regulated systems (Tet-systems), as introduced by Gossen and Bujard 15 in 1992, offer a reliable and robust approach to regulated transgene expression and currently represent the most frequently used inducible gene expression system. The Tet-system is dependent on two genetic elements: (i) the Escherichia coli Tet repressor protein (TetR) that exerts its transcriptional repression by binding to the Tet operator (TetO) and (ii) the presence of tetracycline or its potent analogue doxycycline (Dox) induces a conformational change within TetR and thereby abolishes the interaction with TetO and releases the transcriptional blockade. 15, 16 For eukaryotes, a fusion protein of the activation domain of the herpes simplex virus VP16 protein and the TetR, called transcriptional activator (tTA), has been introduced that induces gene expression by binding to a promoter element (Ptet) placed downstream of TetO and this interaction is disrupted in the presence of Dox (Tet-OFF system). 17 However, for in vivo usage, OFF-systems suffer from two major drawbacks: continuous presence of the activator is required in the quiescent state and the induction kinetic is mainly determined by the rate of drug clearance. Therefore, a modification of four amino acids within the activator was introduced, resulting in a reverse tTA (rtTA) that only binds to Ptet in the presence of Dox (Tet-ON system), 16 and subsequently a number of modifications have been introduced into the rtTA and Ptet elements to reduce the background levels of transgene expression in the Tet-ON system. 18, 19 One area that appears particularly suited for the use of inducible gene expression systems is the transfer of chemotherapy-resistance (CTX-R) genes into haematopoietic stem cells (HSCs) to protect the haematopoietic system from the toxicity of defined anti-neoplastic agents, as for this application transgene expression only is required for the relatively short periods of cytotoxic drugs administration. A number of such CTX-R genes have been identified and for several of them protection of haematopoiesis from the associated cytotoxic agents has been established in murine as well as large animal models. 20, 21 This includes mutant forms of dihydrofolate reductase (mutDHFR), [22] [23] [24] the multidrugresistance type 1 (MDR1) gene coding for the cellular efflux pump p-glycoprotein [25] [26] [27] or the gene coding for the DNA repair protein O 6 -methylguanine methyltransferase. [28] [29] [30] [31] Cytidine deaminase represents another interesting CTX-R gene that protects lymphohaematopoietic cells from the cytotoxic deoxycytidine analogues cytosine-arabinoside (1-b-D-arabinofuranosylcytosine, Ara-C), gemcitabine (2 0 ,2 0 -difluorodeoxycytidine) and 5-azacitabine (5-aza-2 0 deoxycytidine). In particular, Ara-C has been utilized clinically for extended time periods and has established itself as the most effective single agent in the treatment of acute leukaemias. Importantly, a protective effect of human cytidine deaminase (hCDD) gene transfer in the context of Ara-C and gemcitabine application has been established in murine and human clonogenic progenitor cells [32] [33] [34] as well as in a murine in vivo bone marrow transplant model. 35 However, these studies also revealed considerable lymphotoxicity induced by high constitutive hCDD expression in vivo. 35 Thus, in a proof-of-principle study, we have investigated the suitability of Dox-regulated vector constructs to avoid transgenespecific side effects of gene therapy such as the lymphotoxicity associated with hCDD overexpression in the haematopoietic system. We here describe rapid and robust transgene expression upon Dox application with moderate background levels in the Dox-OFF state. This allowed for protection of the haematopoietic system from Ara-C-induced toxicity and at least at the expression level obtained here with the inducible system completely abrogated the lymphotoxicity observed previously in the context of high constitutive hCDD expression.
RESULTS

Efficient transgene induction by Dox in 32D myeloid cells
To investigate inducible hCDD expression, we have generated Dox-regulated third generation self-inactivating (SIN) lentiviral vectors expressing the hCDD-cDNA in combination with an enhanced green fluorescence protein (eGFP)-reporter gene (SIN.Tet.CDD; Figure 1a ) and a control vector expressing only eGFP (SIN.Tet.GFP; Figure 1b) . For both vectors, transgenes are expressed in the presence of Dox (Tet-ON system), and the SIN configuration increases the safety of the vectors and reduces the risk of vector mobilization. 36 To investigate regulated expression of hCDD and eGFP from these constructs, myeloid 32D cells were transduced with either SIN.Tet.CDD or SIN.Tet.GFP in combination with SIN.PGK.rtTA3 (Figure 1c ). Exposure to 2 mg ml À 1 of Dox revealed a transduction efficiency of 30-50% for co-transduced eGFP þ cells and purity of the eGFP þ population subsequently was increased to 497% by fluorescence-activated cell sorting (data not shown).
The dose-response correlation of Dox-induced transgene expression in SIN.Tet.CDD-transduced 32D cells was investigated by exposing these cells for various time-intervals to Dox concentration ranging from 0 to 2.0 mg ml À 1 . As depicted in Figure 2a , administration of 0.2-2.0 mg ml À 1 Dox induced eGFP expression to plateau levels within 24 h (for 2 mg ml À 1 ; see also Supplementary Video 1). Rapid induction of eGFP also was observed at lower Dox concentrations, although exposure to 0.008 or 0.04 mg ml À 1 led to notably reduced mean fluorescence intensities plateau levels. Mean fluorescence intensity levels measured in the presence of 0.002 and 0 mg ml À 1 Dox were indistinguishable, albeit significantly higher than those for nontransduced cells. A similar dependency on Dox dosage, but a clearly delayed induction kinetic, was observed for hCDD (Figure 2b ). In addition, optimal hCDD expression was observed for 0.2-2.0 mg ml À 1 Dox; however, in contrast to eGFP, maximal hCDD expression was observed until days 4-5. Also for hCDD, low background expression in the absence of Dox was detectable, as demonstrated by a faint protein band on day 5.
Inducible CDD expression mediates profound protection against Ara-C in 32D cells Functionality of Dox-inducible hCDD expression was evaluated by exposing SIN.Tet.CDD-or SIN.Tet.GFP-transduced 32D cells to Ara-C after 1 week of preculture in the presence or absence of Dox. In these experiments, SIN.Tet.CDD-transduced cells cultured in the presence of 2.0 mg ml À 1 Dox proved completely resistant to Ara-C concentrations of up to 5000 nM, whereas non-Dox treated control cells or SIN.Tet.GFP-transduced cells were susceptible to Ara-C exposure from 50 nM onwards (Figure 2c ). This correlates to a more than 17-fold increased LD 50 concentration (from 300 to 350 to 45000 nM) even in cells transduced at low MOI and carrying only one copy of the SIN.Tet.CDD provirus. Moreover, as depicted in Figure 2d , hCDD-mediated drug resistance was dependent on the Dox dosage. When SIN.Tet.CDD-transduced 32D cells were exposed to Dox for 72 h, maximal protection from Ara-C was shown for Dox concentration of 0.2 mg ml À 1 (LD 50 42.000 nM Ara-C), and this dose-response curve recapitulated the hCDD induction observed at the protein level. Of note, background hCDD expression in the absence of Dox did not induce relevant protection against Ara-C as LD 50 þ and CD8 þ T, and myeloid cells upon the administration of Dox by drinking water. In all, haematopoietic cell compartments induction of eGFP was detected within 2 days and plateau levels were reached within 13 days. Thereafter, mean fluorescence intensity values remained constant until Dox administration was discontinued. Upon Dox, withdrawal eGFP mean fluorescence intensity values for B, CD4 þ and CD8
þ T, as well as myeloid cells, decreased substantially the first 20 days and reached almost background levels after 45 days (Figure 4c ). Dox-induced hCDD expression protects the haematopoietic system from Ara-C toxicity in vivo To investigate the protective effect conveyed to SIN.Tet.CDDtransduced lymphohaematopoietic cells and their progeny by Dox application, mice receiving Dox for at least 1 month were treated with Ara-C utilizing, a previously described application schedule (500 mg kg
. 35 At the time of treatment, mice had received Dox for at least 1 month. Of note, eGFP transgene expression rates at the time of treatment only were 15-25% for the individual cell compartments. Peripheral blood analysis was performed 3 days in advance and on day 2, 4 and 7 after the last Ara-C treatment. As shown in Table 1 , Dox-induced expression of hCDD led to significantly improved recovery of granulocytes on day 4 (0.6±0.1 versus 0.4±0.1 Â 10 3 per ml; Po0.05) and day 7 (1.9±0.6 versus 1.3±0.3 Â 10 3 per ml; Tet.CDD group was also observed for lymphocytes (day 7 post-treatment), but here differences failed to reach statistical significance (P ¼ 0.08). As with constitutive hCDD expression, 35 no long-term enrichment of vector-transduced cells was observed, when the relative contribution of gene-modified cells to peripheral blood cell compartments before and after Ara-C application was compared (Supplementary Table 1 ). These results were recapitulated in a second independent experiment (data not shown). Figure 5a , efficient expression of the eGFP transgene was observed in all BM-derived stem-and progenitor compartments. EGFP expression also was detected in BM-derived mature and immature B cells, all thymic T-cell fractions ranging from primitive double-negative via doublepositive to more differentiated single-positive CD4 þ or CD8 þ T cells (Figure 5b ) as well as splenic mature B and T cells (Figure 5c ). Furthermore, eGFP expression was observed in spleenderived myeloid cells. Expression of the hCDD transgene in haematopoietic organs of SIN.Tet.CDD animals was evaluated by western blot analysis performed on total organ cell lysates. To compensate for differences in loaded amounts of protein, densitometric analysis assessing hCDD protein levels relative to the levels of vinculin was utilized. Although hCDD expression was undetectable in haematopoietic organs of wild-type animals, these studies clearly demonstrated hCDD expression in the BM, spleen and thymus of mice transplanted with SIN.Tet.CDD-transduced cells (Figure 5d ).
Not surprisingly, effective hCDD expression also was observed on a functional level when Ara-C resistance of progenitor-derived colonies was assessed in clonogenic assays. When total BM cells from two mice transplanted with SIN.Tet.CDD-transduced cells and wild-type C57BL/6 mice were compared, pronounced differences were noted. In particular, virtually all colonies derived from control C57BL/6 mice died at 400 nM Ara-C (B1% surviving colonies), whereas, 32 and 50% of colonies from SIN.Tet.CDD animals survived this treatment (Figure 5e Figure 1) .
No evidence of cellular toxicity including lymphotoxicity following Dox-regulated hCDD expression A major aspect of our study was the prevention of CDD-mediated lymphotoxicity observed previously with constitutive hCDD (over)expression. 35 In these studies, lymphotoxicity manifested primarily as a significantly reduced contribution of gene modified B and T cells to lymphopoiesis. Therefore, we have systematically 
Dox-inducible CDD expression N Lachmann et al
investigated the contribution of gene-modified (that is, eGFP þ ) cells to the various lymphoid cell compartments comparing animals that received either SIN.Tet.CDD-or SIN.Tet.GFPtransduced transplants. Even after Dox administration for up to 8 weeks, no alterations in peripheral blood cell counts including the lymphocyte count were observed (also see Table 1 , day À 3 data). In addition, the relative contribution of gene-modified cells to peripheral blood B, CD4 þ or CD8 þ T and myeloid cells remained fairly constant during the 8 weeks of Dox administration (Figures 6a and b) and, even more important, similar contribution of transduced cells were observed for the myeloid and the lymphoid cell compartment at least at the CDD expression levels achieved with the Dox-inducible system.
DISCUSSION
The study presented here demonstrates efficient Dox-regulated transgene expression in myeloid 32D and primary BM cells in vitro as well as in a murine bone marrow transplant model. In the transplant model, Dox-induced CDD expression not only significantly reduced Ara-C-induced myelotoxicity but at least at the expression level obtained with the Dox inducible system also abrogated the lymphotoxicity observed previously with constitutive hCDD expression. 35 Clearly, high transgene induction in the presence and tight regulation in the absence of Dox, that is, an adequate therapeutic window, constitutes a major prerequisite for the successful use of Dox-regulated vector systems. To this point we not only have shown robust and rapid transgene expression upon Dox application but also moderate background levels in the Dox-OFF state. Importantly, the minor hCDD background levels observed in the OFF state had no unwanted side effect in vitro or in vivo, and in the in vitro situation not even correlated to an increased protection capacity. Furthermore, effective shut-down of eGFP as well as hCDD transgene expression was observed upon Dox cessation. The prolonged shut-off kinetic for hCDD most likely reflects differences in protein half life, whereas the more rapid detection of GFP upon Dox administration easily can be explained by the higher sensitivity of flow-cytometric versus western blot analysis.
In our study, lack of cell type-specific toxicity and particularly lymphotoxicity was indicated by normal cell counts and, more importantly, similar contribution of gene-modified cells to all lymphohaematopoietic cell compartments. This is important as in previous studies, using conventional LTR-driven g-retroviral vectors CDD-induced lymphotocity was identified by a significantly reduced relative contribution of gene marked cells to lymphoid as compared to myeloid compartments. 35 A potential biochemical basis for this observation has been identified recently, when selective toxicity within the lymphoid compartment was observed in mice lacking the deoxycytidine kinase gene. 37 In the deoxyribonucleotide salvage pathway, deoxycytidine kinase catalyses the phosphorylation of deoxycytidine to the monophosphate state and thereby competes with cytidine deaminase for this substrate. Thus, lack of deoxycytidine kinase as well as overexpression of cytidine deaminase both can be expected to diminish production of deoxycytidine triphosphate, the final product of the nucleotide salvage pathway. Although the deoxyribonucleotide salvage pathway is dispensable for most developmental processes, including embryo-and organogenesis, it appears to have a critical role during early T-and B-cell development when T-cell receptor-or VDJ-recombination is followed by massive cellular proliferation. 37 Nevertheless, the evidence gathered in the present study does not necessarily establish a causal relationship between the lack of lymphotoxicity and the Dox-regulation of CDD expression, in particular as no control group expressing hCDD constitutively in the haematopoietic system was employed. Thus, other explanations and foremost lower levels of CDD expression from the Doxinduced pTet as compared to the SFFV-LTR promoter have to be considered. At least in 32D cells, indeed lower CDD expression in SIN.Tet.CDD-versus RSF91.CDD-transduced cells have been observed (own unpublished date). Thus, the CDD levels achieved by our Dox-regulated system, while allowing for myeloprotection, may be too low to cause lymphoid toxicity. This notion is supported by the fact that in the present study even prolonged Dox application for up to 90 days was not associated with lymphotoxic side effects.
No enrichment of hCDD-positive cells was observed in our model following Ara-C application. This is in line with previous studies also failing to show consistent enrichment of hCDDpositive cells by short-term high-dose Ara-C application in an in vivo model 35 and probably reflects the relative quiescence of primitive stem cell populations in steady-state haematopoiesis and the S-phase-specific cytotoxic activity of Ara-C. 38, 39 Indeed, we recently demonstrated that toxicity of short-term high-dose Ara-C application primarily effect haematopoietic precursor and late progenitor populations, while stem cells or long-lived progenitors remained relatively unaffected. 40 Ara-C toxicity for primitive haematopopietic cells can be augmented, however, by prolonged low-dose Ara-C application (for example, 30-60 mg kg À 1 daily for 10-20 days). In this setting at least transient enrichment of CDD-transduced haematopoietic cells has been achieved. 40 Dox-regulated transgene expression also offers a way to reduce the genotoxic side effects of integrating vector-based gene therapy approaches and particularly the risk of insertional mutagenesis. As the activation of neighbouring oncogenes by vector integrations clearly is linked to vector-associated enhancer activity, 41 the temporary nature of the transgene expression from inducible system should substantially reduce this risk. In addition, state-of-the-art third generation SIN lentiviral constructs were employed in our study. In comparison to conventional LTR-driven g-retroviral vectors, which preferentially integrate into generegulatory regions, 42, 43 these constructs offer improved safety 
Mean values of transplanted mice±s.e.m. are given.
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features as lentiviral vectors not only are less likely to integrate in the vicinity of promoter elements and CpG islands but also allow for reduced ex vivo cell manipulation times. Moreover, the SIN configuration permits the usage of alternative regulatory sequences, such as physiological endogenous promoters, that further reduce the genotoxic risk by limiting the range of influence of enhancer activity or miRNA targets to increase cell-type specificity. 41, 44, 45 Clearly, immunogenicity of the continuously expressed transactivator protein represents a concern for a potential clinical application of Dox-regulated vector system, and studies in nonhuman primates indicate that in certain situations, the Tetactivator may elicit a cellular and humoral immune response. 46, 47 Given the therapeutic efficacy of Ara-C, particularly in haematopoietic malignancies, this setting also represents the most likely scenario for the clinical application of Dox-regulated CDD expression. This is probably less problematic in myeloablative and in particular allogeneic HSC-transplant settings, where de novo formation of the immune system including tolerance induction to novel antigens should prevent immune reactions to components of the Tet-system. 48 Immunogenicity may become more problematic, however, with strategies aiming at the delivery of Tet-regulated transgenes to non or only partially myeloablated hosts. In this situation, immunomodulatory approaches based on regulatory T cells or tolerogenic dendritic cells may be required. 49 Another hurdle for the clinical application of Dox-inducible transgene expression systems is the transfer of two expression cassettes to HSCs. This appears problematic not only in terms of efficacy but also with regard to safety considerations, as more viral integrations sites could translate into an increased risk of insertional mutagenesis. Currently, the most promising solution to this problem are all-in-one vector constructs, which allow for simultaneous expression of the TetR as well as an Tet-regulated transgene of interest from two different transcription units incorporated into the same vector construct. 18, 50, 51 Thus, a number of issues still have to be addressed before the clinical applications of Dox-regulated gene expression systems in HSC gene therapy. However, once these problems are solved, this strategy holds considerable promise to reduce insertion-triggered genotoxic as well as transgene-specific side effects of gene therapy for approaches in which transgene expression is only required temporarily, such as the transgenic expression of drugresistance genes in the haematopoietic system.
MATERIALS AND METHODS Animals
C57BL6/J mice were obtained from Charles River Laboratories (Sulzfeld, Germany) and B6.Cg-Gt(ROSA)26Sor tm1(rtTA*M2)Jae /J (R26-M2rtTA) transgenic mice from the central MHH animal facility (Hannover, Germany). All mice were kept in IVC racks (Allentown Inc., Mö mbris, Germany) in pathogenfree conditions. All animal experiments were approved by the local animal welfare committee and performed according to their guidelines.
Lentiviral vectors
Lentiviral constructs were based on third generation SIN lentiviral vectors modified by insertion of a woodchuck hepatitis virus-derived posttranscriptional-regulatory element (wPRE).
52 SIN.Tet.GFP (also called pRRL.PPT.pTet.eGFP.pre*) was constructed by cloning the Tet promoter 15 as an XhoI/AgeI fragment (amplified by primers 5 0 Tet xho 5 0 -GCCT CGAGCTAGACGAGTTTACTCCCTATCAGTGATAGAGAACGATGTC-3 0 and 3
0
Tet age 5 0 -CGACCGGTGCGATCTGACGGTTCACTAAACGAG-3 0 ; restriction sites underlined) into pRRL.PPT.SF.GFP.pre* 53 substituting for the SFFV U3 promoter. To generate SIN.Tet.CDD, the cDNA of hCDD (Open Biosystem, IHS1380-OB-97652440, Epsom, UK) was cloned via AgeI/SalI into the SIN.Tet.GFP backbone followed by an exchange of eGFP for IRES.eGFP using SalI restriction. For generation of SIN.PGK.rtTA3, the reverse transactivator rtTA3 (ref. 17) was amplified by PCR from a pTRIPZ vector (Open Biosystems), using primers 5 0 rtTA3 BamHi 5 0 -GTGGA TCCGCCACCATGTCTAGGCTGGACAAGAGCAAA-3 0 and 3 0 rtTA3 SalI 5 0 -TTGT CGACTTACCCGGGGAGCATGTCAAGGT-3 0 and cloned into pRRL.PPT.PG K.GFPpre 52 (kindly provided by Luigi Naldini, Milano). All PCR products were verified by sequencing.
Production of viral supernatants and titration Viral supernatants were generated by transfection of 293T cells as described previously. 41, 54 In brief, 7 Â 10 6 293T cells cultured in high-glucose Dulbecco's modified Eagle's Medium (PAA, Cö lbe, Germany) supplemented with 10% fetal calf serum, 100 U ml In vitro experiments 32D cells. Murine 32D cells were cultured in RPMI-1640 supplemented with 10% fetal calf serum, 100 U ml À 1 penicillin/streptomycin (Pen/Strep), 2 mmol l À 1 glutamine (all PAA) and 2 ng ml À 1 rmIL-3 (Peprotech, Hamburg, Germany). Cells were co-transduced with VSVg pseudotyped lentiviral particles (SIN.Tet.GFP/SIN.PGK.rtTA3 or SIN.Tet.CDD/ SIN.PGK.rtTA3) in the presence of 10 mg ml À 1 protaminsulfate (Roth, Karlsruhe, Germany) at 37 1C. Twenty-four hours after transduction, cells were exposed to 2 mg ml À 1 of Dox for 48 h and subsequently sorted for eGFP expression (FACS AriaIIu, Becton Dickinson) to establish transgenic 32D cells of purity 497%. Following Dox-starvation for 2-4 weeks, transgenic 32D cells were stimulated with different Dox concentrations and transgene expression was analysed by flow cytometry using FACSCalibur (Becton Dickinson) or by western blot analysis at different time points. Dox withdrawal studies were performed using transgenic 32D cells stimulated with Dox for 2-4 weeks. Transgene expression was analysed by flow cytometry using FACSCalibur or by western blot analysis. For in vitro protection as well as LD 50 analysis, transgenic 32D cells were cultured for 3 days in the presence of different concentrations of Ara-C (Alexan, Neocorp AG, Weilheim, Germany) and either 2 mg ml À 1 or different concentrations of Dox, respectively. Cell survival was assessed by flow cytometry analysis using propidium iodide staining (Sigma Aldrich).
Lineage negative BM cells. BM cells were isolated from femura and tibiae of 12-24 week-old B6.Cg-Gt(ROSA)26Sor tm1(rtTA*M2)Jae /J (R26-M2rtTA) transgenic mice. Lin À cells were purified using MACS separation (Lineage Cell depletion kit, Miltenyi, Bergisch Gladbach, Germany) and prestimuled for 24 h in StemSpan medium (StemCell Technologies, Cologne, Germany) supplemented with 10 ng ml À 1 rmSCF, 20 ng ml À 1 rmTPO, 20 ng ml Murine in vivo bone marrow transplant model Donor cell isolation, transduction and transplantation. Lin À BM cells of 12-24 week-old R26-M2rtTA transgenic mice were isolated and transduced as described above. Forty-eight hours after transduction, cells were transplanted into tail veins of lethally (10 Gy) irradiated 10-12 weeks-old female C57BL6/J mice (Charles River Laboratories). Haematologic reconstitution was confirmed by peripheral blood counts 24-30 days after transplantation.
Peripheral blood sampling and analysis. For peripheral blood analysis, 10 ml (for peripheral blood counts) or 10-20 ml (for flow cytometric analysis of eGFP expression) of blood was taken from the retroorbital plexus. Blood counts were evaluated on veterinary blood cell counter (VetABC, Scil Animal Care, Viernheim, Germany). Peripheral blood eGFP þ cells were analysed by flow cytometry using LSRII (Becton Dickinson, antibodies given in Supplementary Table 2) following red cell lysis. Dox application. After haematologic reconstitution, animals received drinking water supplemented with 2 mg ml À 1 Dox and 25% sucrose (Roth) for 4-12 weeks, to induce transgene expression and to perform in vivo protection analysis. Thereafter, Dox was withdrawn for 4-8 weeks before, mice were treated again with Dox by drinking water for at least 4 weeks before final analysis.
Ara-C application. After 4 weeks of Dox administration, animals were treated intraperitoneally with 500 mg kg À 1 Ara-C for 4 consecutive days. To investigate haematopoietic recovery, peripheral blood analysis was performed on day 2, 4 and 7 after the last Ara-C dose.
Analysis of haematopoietic subcompartments from BM, spleen and thymus. At 16-24 weeks after transplantation, animals were killed and eGFP þ cells from phenotypically defined cell subcompartments of BM, spleen and thymus were analysed in addition to peripheral blood, using flow cytometry. In brief, cells were isolated from different haematopoietic organs using cell strainer (Becton Dickinson), washed with PBS supplemented with 2 mM EDTA and 2% fetal calf serum followed by a 1-min red blood cell depletion step utilizing lysis buffer (0.83% NH4Cl, 0.5% KHCO3, 0.5 mM EDTA) and stained for 45 min with conjugated antibodies. All antibodies were used as recommended by the manufacturer. Data were analysed using LSR II (Becton Dickinson) and FlowJo software (TreeStar, Ashland, OR, USA) Secondary transplantation. A total of 20-30 Â 10 6 BM cells from primary recipients were transplanted by tail vein into lethally irradiated (10 Gy) 10-12 weeks-old female C57BL6/J mice. Transgenic eGFP expression in peripheral blood cells was analysed 6-8 weeks days after transplantation and including 2 weeks of Dox treatment as described above.
Western blot analysis of hCDD expression
Protein samples from SIN.Tet.CDD-or SIN.Tet.GFP-transduced 32D and Lin À BM cells or BM, thymus and spleen cells of animals in the SIN.Tet.CDD group 24-32 weeks post-transplantation were prepared using RIPA-Buffer (Sigma-Aldrich) and protease inhibitor (Roche Diagnostics, Manheim, Germany). Subsequently, 10 mg of protein lysates were loaded on a 12% SDS gel electrophoresis. Protein samples from SIN.Tet.CDD-transplanted animals were prepared using RIPA buffer according to the manufacturer's suggestion. Subsequently, blots were incubated over night at 4 1C with either rabbit polyclonal antibody anti-hCDD (Ab56053-100, AbCam, Cambridge, UK) according to manufacturer's description or a mouse IgG monoclonal anti-vinculin antibody (Sigma Aldrich) 1:1000, respectively. Secondary staining was performed at room temperature for 1 h using peroxidase-conjugated donkey anti-rabbit or donkey anti-mouse antibodies (both Jackson ImmunoResearch, Newmarket, Suffolk, UK). To detect peroxidase activity, SuperSignal West Femto Substrate Kit (Thermo Fisher Scientific, Schwerte, Germany) and universal hood II (BioRad, Munich, Germany) were used.
Time-lapse video-microscopy
Continuous live cell imaging of Dox-dependent eGFP reporter expression was performed on SIN.Tet.GFP-transduced 32D cells. For Dox-ON kinetic, transduced cells starved of Dox for 4 or more weeks were exposed to 2 mg ml À 1 Dox on day 0. For Dox-OFF kinetic, transduced cells were cultured in the presence of 2 mg ml À 1 of Dox for 4 weeks or more before Dox was withdrawn. To avoid floating of suspension cells during the imaging process, 5 Â 10 4 cells were immobilized in non-adhesive triangular microcavities. Brightfield and fluorescence images were captured in 15 min intervals for at least 65 h for Dox-ON or 137 h for Dox-OFF using the AxioObserver Z1 fluorescence microscope (Zeiss, Jena, Germany) with a 37-1C humidity chamber and 5% CO 2 levels. Video analysis was performed with Axiovision Software 4.70 (Zeiss).
Integration analysis
Genomic DNA from transduced or non-transduced cells was isolated using GenElute Mammalian Genomic DNA Miniprep Kit (Sigma-Aldrich, Steinheim, Germany). Mean copy number was determined by quantitative PCR using primers detecting woodchuck post-transcriptional element (wPRE) and polypyrimidine tract binding protein 2 (PTBP2) as internal reference. Quantitative PCR was performed using FAST SYBR Green (Stratagene, Santa Clara, CA, USA) on a StepOnePlus (Applied Biosystems, Carlsbad, CA, USA). A plasmid standard containing the sequences for wPRE and PTBP2 was used for quantification.
Statistical analysis
Statistical analysis was performed using Prism 5 software (GraphPad, La Jolla, CA, USA). Unless otherwise noted Student's t-test (unpaired, onetailed) was used.
